ThyCa's Research Grant Awards - Researchers, Institutions, Projects06/2012
At ThyCa: Thyroid Cancer Survivors’ Association, Inc., we’re committed to funding research to help cure all types of thyroid cancer. Thanks to generous contributions, ThyCa has awarded new thyroid cancer research grants every year since 2003.
Elizabeth G. Grubbs, M.D., M.S., The University of Texas M. D. Anderson Cancer Center, Houston, Texas, for the project titled “Fusion Oncogenes as Drivers of Medullary Thyroid Cancer.” This project focuses on the role of RET fusion in MTC tumorigenesis, with the overall goal of showing that this gene rearrangement may predict biological behavior in MTC and that this pathway may be a viable target to (1) predict responses to targeted MTC therapy, (2) better stratify MTC patient outcomes and, for non-RET driven tumors, and (3) potentially offer a more rational approach to individualization of therapy.
Jason D. Prescott, M.D., Ph.D., The Johns Hopkins University School of Medicine, Baltimore, Maryland for the project “Development of a High Throughput in vivo Screening System for Small Molecule Activators of Thyroid Differentiation: Identification and Targeting of New Molecular Pathways Involved Thyroid Cancer Progression.” This project seeks to (1) identify new molecular pathways and mechanisms contributing to aggressive thyroid cancer and progression involving the BRAF protooncogene and (2) assess compounds in a large drug library for their anti-thyroid tumor activity and their molecular actions.
Brian R. Untch, M.D., Memorial Sloan Kettering Cancer Center, New York, New York, for the project titled “Mechanisms of response and resistance to farnesyltransferase inhibition in HRAS-driven thyroid tumors.” Dr. Untch notes that HRAS mutations are the second most common type of RAS mutation found in thyroid cancer and can be found in different types of cancer. Building on prior research with poorly differentiated and anaplastic thyroid cancer, the study will explore a class of drugs that are preferentially active against HRAS as compared to other mutations, to explore the mechanisms of adaptive and acquired resistance to a drug targeted against RAS in vitro and in vivo in a genetically accurate model of cancer. Dr. Untch’s group is also developing clinical trials with these drugs specifically for HRAS-mutant disease. This grant is this year’s Ric Blake Memorial Thyroid Cancer Research Grant, named for ThyCa Co-Founder Ric Blake, in honor of his dedication and commitment to ThyCa and to our goal of better futures for everyone with thyroid cancer, everywhere in the world.
- Nicole Chau, M.D., Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts, for the project “Overcoming Resistance to RET inhibitors in Medullary Thyroid Cancer.” Dr. Chau is a medical oncologist and the goal of this project is to compare the efficacy of current and novel RET inhibitors against specific oncogenic RET mutations in Medullary Thyroid Cancer and to predict and study acquired resistance mechanisms.
- Brittany Bohinc, M.D., Duke University Hospital, Durham, North Carolina, for the project “Overexpression of LGR4 and LGR5 in Human Thyroid Cancer Promotes Wnt/β-Catenin Signaling and is Associated with Tumor Aggressiveness.” This project will focus on understanding the role of specific pathways and markers in nodal metastases and aggressive tumor behavior, with this understanding aiding potential development of novel therapeutics in metastatic papillary thyroid cancer that is unresponsive to current therapies. This grant is the 2013 Ric Blake Memorial Thyroid Cancer Research Grant.
- Jaroslaw Jendrzejewski, M.D., Ohio State University Columbus, Ohio for the project “Analysis of locus 14q13.3 in search of mutations predisposing to Papillary Thyroid Carcinoma (PTC).” This two-step project aims to uncover mutations by combining second-generation sequencing with bioinformatic analysis of 14q13.3 locus, which genome wide association studies have identified as one of the most important in genetic predisposition to PTC.
- Niklas Finnberg, Ph.D., Penn State Hershey Cancer Institute, Hershey, Pennsylvania, for the project titled "Sorafenib and Quinacrine as Potential Combination for Anaplastic Thyroid Carcinoma."
- Aime Franco, Ph.D., University of Arkansas for Medical Sciences, Little Rock, Arkansas, for the project titled "The Role of RAS versus RAF in Thyroid Cancer Development and Progression."
- Andreas Lundqvist, Ph.D., Cancer Center Karolinska, Stockholm, Sweden, for the project titled "Study the Role of Natural Killer Cells in Anaplastic Thyroid Carcinoma." Dr. Lundqvist is the recipient of the Ric Blake Memorial Thyroid Cancer Research Grant.
- ”Naifa L. Busaidy, M.D., Assistant Professor in the Department of Endocrine Neoplasia & Hormonal Disorders at the University of Texas – M.D. Anderson Cancer Center in Houston, Texas, for the project titled “A PI3K Based Phophoproteome Signature To Predict Prognosis and Response to Therapy in BRAF Mutant Papillary Thyroid Carcinoma.”
- Joanna Klubo-Gwiezdzinska, M.D., Ph.D., Endocrine Research Fellow, Washington Hospital Center/Georgetown University, Washington, D.C., for the project, “The Role of the Translocator Protein (TSPO) in the Thyroid Cancer Response to Treatment.”
- Carmelo Nucera, M.D., Ph.D., Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Massachusetts, for the project “Targeting BRAFV600E with an Orally Available Selective Inhibitor in Novel In Vitro and In Vivo Preclinical Models of Human Papillary Thyroid Cancer.
- Rozita Bagheri-Yarmand, Ph.D., University of Texas M.D. Anderson Cancer, Houston, Texas, for the project titled “Center Activating Transcription Factor 4 (ATF4), a Novel Putative Tumor Suppressor Gene in Medullary Thyroid Cancer."
- Tania Pilli, M.D., University of Illinois at Chicago, Chicago, Illinois, for the project titled “The Role of MADD, an IG20 Gene Splice Variant, and Its Potential Use as Therapeutic Target in the Anaplastic Thyroid Cancer.”
- Dingxie Liu, M.D., Ph.D., Johns Hopkins University School of Medicine, Baltimore, Maryland, for the project titled “Dually Targeting the MAP Kinase and PI3K Pathways in Thyroid Cancer – Testing of a Novel Therapeutic Approach.”
- Martin Walter, M.D., University Hospital Basel, Basel, Switzerland, for the project titled “Somatostatin-coupled Nanoparticles for Imaging and Therapy of Medullary Thyroid Cancer.”
- Mike S. Fenton, Ph.D., University of California Los Angeles (UCLA)/Veterans Affairs West Los Angeles Health Care System, Los Angeles, California, for project on promoter gene regulation of the sodium/iodide symporter (NIS) gene expression in papillary thyroid cancer.
- Libero Santarpia, M.D., Ph.D., University of Texas M.D. Anderson Cancer Center, Houston, Texas, for project on identifying the target genes of six microRNAs (miRNA) in medullary thyroid cancer.
- Krystian Jazdzewski, M.D., Ph.D., Medical University of Gdansk, Poland, and Visiting Scientist, Ohio State University, Columbus, Ohio, for research on the role of miR146a in papillary thyroid carcinoma.
- Mabel Ryder, M.D., Memorial Sloan-Kettering Cancer Center, New York, New York, for research on the role of Tumor-Associated Macrophages (TAMs) on thyroid cancer progression.
- Lionel Groussin, M.D., Ph.D., Cochin Institut, Paris, France, for research focusing on two specific enzymes in thyroid cells and their possible roles in suppressing thyroid cancer.
- Xianmin Xia, Ph.D., Johns Hopkins University School of Medicine, Baltimore, Maryland, for research on the effect of a small portion of a tumor suppressor protein on the proliferation of human medullary thyroid cancer cells, as well as poorly differentiated papillary thyroid cancer cells and anaplastic thyroid cancer cells.
- Matthias Schott, M.D., Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany, for project titled “Induction of Cytotoxic Immunity in Medullary Thyroid Carcinoma by Dendridic Vaccination.”
- Erich M. Sturgis, M.D., University of Texas M.D. Anderson Cancer Center, Houston, Texas, for project titled “Radiation Response Genotype and Risk of Papillary Thyroid Cancer: A Case-Control Study.”
- Sareh Parangi, M.D., Harvard Medical School, Boston, Massachusetts, for project titled "Antiangiogenic Therapy of Thyroid Cancer."
- Xiulong Xu, Ph.D., Rush-Presbyterian-St. Luke's Medical Center. Chicago, Illinois, for project examining the relationship between a gene mutation and papillary thyroid cancer.
ThyCa’s grants are the first-ever thyroid cancer research grants to be funded entirely by thyroid cancer patients, caregivers, and friends. The grant recipients are selected by an independent expert panel of the American Thyroid Association. The ThyCa grants are open to researchers and institutions worldwide.
You’re invited to help support the Rally for Research. For details, visit the Rally for Research page.